Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

Abstract Background Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor clinical prognosis. Inhibitors of transcriptional CDKs are currently under thorough investigation for application in the treatment of multiple cancer types, including breast...

Full description

Bibliographic Details
Main Authors: Vera E. van der Noord, Wanda van der Stel, Gijs Louwerens, Danielle Verhoeven, Hendrik J. Kuiken, Cor Lieftink, Melanie Grandits, Gerhard F. Ecker, Roderick L. Beijersbergen, Peter Bouwman, Sylvia E. Le Dévédec, Bob van de Water
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer
Transcriptional cyclin-dependent kinases
CDK12/13
THZ531
ABCG2
Drug resistance
Online Access:https://doi.org/10.1186/s13058-023-01648-x

Internet

https://doi.org/10.1186/s13058-023-01648-x

Similar Items